Hyperfine Announces First Peer-Reviewed Publication Demonstrating Significant Economic Benefits of Using the Swoop® AI-Powered Portable MRI System in Acute Hospital Care

January 6, 2026

GUILFORD, Conn.--(BUSINESS WIRE)--Jan. 6, 2026-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the first peer-reviewed publication in *Clinical Neuroimaging*, demonstrating the positive economic impact of implementing the portable Swoop® MR imaging system in the acute care setting of the hospital.

A 12-month retrospective analysis included 143 patients and was conducted at Jefferson Abington Hospital, a 665-bed Level II trauma center and comprehensive stroke center within the Jefferson Health System. The analysis examined the cost savings and workflow efficiencies achieved by integrating the Swoop® system in critical and emergency care settings. The analysis found that the use of the Swoop® system eliminates the need for patients to transition to MR-compatible equipment and significantly reduces MRI wait times in the ICU and ED, resulting in measurable cost savings and improved patient progression within the hospital. The combined benefits of cost avoidance, increased throughput, and time savings serve as strong fundamental drivers of a compelling health economic profile for hospitals. Together, these efficiencies have a direct impact on the return on investment for the Swoop® system, which has the potential to be realized in a significantly shorter timeframe than traditional capital equipment.

As part of transporting and preparing ICU patients for a conventional MRI, clinicians transition patients to MR-compatible equipment, which involves the use of extension tubing, cables, and electrodes at a cost averaging $590 per patient. Hospitals could entirely avoid this cost by performing the scan directly in the ICU with the Swoop® system. Depending on the utilization of portable MRI, cost savings could range from tens to hundreds of thousands of dollars annually for a hospital. Furthermore, wait times for MRI were reduced by an average of eighteen hours across ICU and ED patients, thus accelerating the time to diagnosis for patients at risk of neurological conditions. This time reduction addresses two significant hospital challenges—the length of stay of ICU patients and the ED boarding crisis facing the majority of acute care facilities.

Dr. Michael Lemole, Director of the Farber Institute for Neuroscience at Jefferson Abington Hospital and a recognized expert in neurosurgical innovation, commented on the significance of this economic impact analysis, “Implementing portable MRI into our hospital has not only improved patient care through faster, safer imaging—it has also proven to be financially compelling for hospital administrators.” The findings underscore how the Swoop® system, the world’s first FDA-cleared portable MRI device, is reshaping neuroimaging by enabling rapid, bedside brain imaging without the logistical delays and costs associated with transporting patients to fixed high-field MRI suites.

“This publication marks a critical milestone in validating not only the clinical utility but also the economic value of portable brain MRI technology,” said Rafael Donnay, Hyperfine Senior Vice President of Hospital Business. “We’re proud to see the Swoop® system deliver meaningful impact for both patients and hospital operations, and with this data now published, hospital staff has access to a compelling and detailed data set to evaluate how the use of the Swoop® system can benefit their institution.”

Healthcare systems are under growing pressure to improve both efficiency and quality of care. The Jefferson Abbington data included in this peer-reviewed publication illustrate how the use of the portable Swoop® system can contribute to making neurological care more cost-effective and efficient in acute and emergency care settings within the hospital. The Jefferson Abington experience offers an evidence-based roadmap for hospitals seeking to enhance imaging access while optimizing operational performance.

The full journal article is available here: https://onlinelibrary.wiley.com/doi/10.1002/neo2.70046

For more information about the Swoop® Portable MR Imaging® system, please visit HyperfineMRI.com.

About the Swoop® Portable MRI Systems
The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results

to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the *Swoop*® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260105161202/en/

Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io

Investor Contact
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com

Source: Hyperfine, Inc.